Jane Street’s ADC Therapeutics ADCT Stock Holding History

Jane Street’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.6K	Sell	61,267 -80,796	-57%	-$236K	﹤0.01%	10815
2026 Q1	$533K	Sell	142,063 -57,701	-29%	-$227K	﹤0.01%	7904
2025 Q4	$705K	Sell	199,764 -288,104	-59%	-$1.17M	﹤0.01%	6942
2025 Q3	$1.95M	Buy	+487,868	New	+$1.54M	﹤0.01%	4985
2024 Q4	–	Sell	-53,126	Closed	-$167K	–	9279
2024 Q3	$167K	Buy	53,126 +38,859	+272%	+$123K	﹤0.01%	8754
2024 Q2	$45.1K	Sell	14,267 -12,717	-47%	-$50.5K	﹤0.01%	8934
2024 Q1	$121K	Sell	26,984 -74,276	-73%	-$274K	﹤0.01%	8454
2023 Q4	$168K	Buy	+101,260	New	+$93.4K	﹤0.01%	8333
2023 Q3	–	Sell	-16,467	Closed	-$35.4K	–	8534
2023 Q2	$35.4K	Sell	16,467 -9,117	-36%	-$20.5K	﹤0.01%	8280
2023 Q1	$49.9K	Buy	+25,584	New	+$94.4K	﹤0.01%	8453

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street's ADCT Position: Q2 2026 in Review

Jane Street reduced its ADC Therapeutics (ADCT) stake by 57% in Q2 2026, selling an estimated $236K and leaving 61,267 shares worth $65.6K. The position accounts for ﹤0.01% of the portfolio, ranked #10815.

Jane Street first reported a position in ADCT in Q1 2023 and has held it in 10 quarters since. The position peaked at $1.95M in Q3 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Jane Street held 61,267 shares of ADC Therapeutics worth $65.6K as of Q2 2026.
Jane Street sold 80,796 ADC Therapeutics shares in Q2 2026, an estimated $236K.
ADC Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10815 holding.
Jane Street first reported a position in ADC Therapeutics in Q1 2023 and has held it in 10 quarters since.
Jane Street's ADC Therapeutics position peaked at $1.95M in Q3 2025.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.